- Stocks
- Pharma & Healthcare
- Jeena Sikho Lifecare
Jeena Sikho Lifecare share price
NSE: JSLLPharma & HealthcareMedical Care Facilities
Jeena Sikho Lifecare at a glance
Jeena Sikho Lifecare (NSE: JSLL) closed at ₹367.20 on 19 Oct 2026, down 5.77% on the day. With a market capitalisation of ₹4,564 Cr, it ranks 830th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 20.7× trailing earnings, against a return on equity of 26.9% in FY23. Over the past year the share price has fallen 51.9%. Its 52-week range is ₹359.75 (9 Oct 2026) to ₹835.00 (7 Nov 2025); the last close is 56.0% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹216 Cr (+54.8% year on year) and net profit ₹45 Cr (+77.9%), on a consolidated basis. Promoters held 63.62% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹4,564 CrRank 830 on NSE
- P/E (trailing)
- 20.7×
- Price to book
- 3.18×FY23
- EPS (TTM)
- ₹17.85to Q4 FY26
- ROE
- 26.9%FY23
- ROCE
- 35.6%FY23
- Debt to equity
- 0.01FY23
- Net profit margin
- 16.4%FY23
- Book value / share
- ₹91.09FY23
- 52-week high
- ₹835.007 Nov 2025
- 52-week low
- ₹359.759 Oct 2026
- 1-year return
- −51.9%
- RSI (14-day)
- 21.8
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −5.77% | −5.2% | −25.2% | −35.9% | −51.9% |
Jeena Sikho Lifecare quarterly results
| Quarter | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|
| Revenue | ₹139 Cr | ₹174 Cr | ₹190 Cr | ₹222 Cr | ₹216 Cr |
| Revenue YoY | — | — | — | — | +54.8% |
| Net profit | ₹25 Cr | ₹51 Cr | ₹59 Cr | ₹67 Cr | ₹45 Cr |
| Net profit YoY | — | — | — | — | +77.9% |
| Net margin | 18.2% | 29.4% | 30.9% | 30.0% | 20.9% |
| EPS | ₹2.04 | ₹4.13 | ₹4.73 | ₹5.36 | ₹3.63 |
Jeena Sikho Lifecare financials
| Item | FY12 | FY22 | FY23 |
|---|---|---|---|
| Revenue | ₹147 Cr | ₹147 Cr | ₹205 Cr |
| Operating profit | ₹15 Cr | ₹15 Cr | ₹44 Cr |
| Net profit | ₹11 Cr | ₹11 Cr | ₹34 Cr |
| EPS (₹) | ₹11.00 | ₹11.00 | ₹25.00 |
| Cash from operations | ₹0 Cr | ₹16 Cr | ₹15 Cr |
| Total debt | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Shareholders' equity | ₹37 Cr | ₹37 Cr | ₹126 Cr |
Jeena Sikho Lifecare shareholding pattern
| Holder | 11 Aug 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 63.53% | 63.61% | 63.62% | 63.62% | 63.62% |
| Foreign institutions | 5.99% | 6.59% | 6.31% | 6.17% | 4.78% |
| Domestic institutions | 0.18% | 0.15% | 0.11% | 0.46% | 0.36% |
| Non-institutions | 30.30% | 29.65% | 29.96% | 29.76% | 31.23% |
Jeena Sikho Lifecare vs peers
The listed Pharma & Healthcare companies nearest to Jeena Sikho Lifecare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NOVARTINDNovartis India | ₹1,919.80 | +2.07% | +245.9% | ₹4,740 Cr | 50.9 | — |
| ZOTAZota Health Care | ₹1,361.00 | −2.51% | −7.1% | ₹4,713 Cr | — | — |
| RPGLIFERPG Life Sciences | ₹2,849.00 | −2.60% | +22.6% | ₹4,712 Cr | 40.9 | — |
| JSLLJeena Sikho Lifecare | ₹367.20 | −5.77% | −51.9% | ₹4,564 Cr | 20.7 | — |
| ORCHPHARMAOrchid Pharma | ₹891.00 | −1.98% | +19.3% | ₹4,519 Cr | 217.8 | — |
| GUFICBIOGufic Biosciences | ₹404.00 | +0.50% | +10.7% | ₹4,051 Cr | 63.1 | — |
| SMSPHARMASMS Pharmaceuticals | ₹432.55 | −3.90% | +57.6% | ₹4,051 Cr | 38.8 | — |
Ask anything about Jeena Sikho Lifecare
Pivot answers on the live chart with evidence you can check, and tests strategies against JSLL's own history. Try: “Why has JSLL moved over the last three months?” · “Backtest a 50-day moving-average crossover on JSLL over five years” · “Compare JSLL with NOVARTIND on margins and valuation”
Frequently asked questions about Jeena Sikho Lifecare
What is the share price of Jeena Sikho Lifecare today?
Jeena Sikho Lifecare (NSE: JSLL) last closed at ₹367.20 on 19 Oct 2026. Its 52-week high is ₹835.00 and its 52-week low is ₹359.75.
What is the market cap of Jeena Sikho Lifecare?
Jeena Sikho Lifecare's market capitalisation is ₹4,564 Cr (₹4,564 Cr) at the 19 Oct 2026 close, ranking 830th among the NSE companies Pivot tracks.
What is the P/E ratio of Jeena Sikho Lifecare?
Jeena Sikho Lifecare trades at a trailing P/E of 20.7. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 50.9.
What is the ROE and ROCE of Jeena Sikho Lifecare?
Return on equity was 26.9% in FY23 and return on capital employed was 35.6% in FY23 (consolidated figures).
Is Jeena Sikho Lifecare a debt-free company?
Jeena Sikho Lifecare is close to debt-free: its debt-to-equity ratio was 0.01 in FY23.
What were Jeena Sikho Lifecare's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Jeena Sikho Lifecare reported revenue of ₹216 Cr, +54.8% year on year, and net profit of ₹45 Cr, +77.9% year on year.
How has Jeena Sikho Lifecare stock performed over the last year?
Jeena Sikho Lifecare's share price has fallen 51.9% over the past year, −35.9% over three months and −25.2% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Jeena Sikho Lifecare?
As of 30 Jun 2026: promoters 63.62%, foreign institutions 4.78%, domestic institutions 0.36%, non-institutions 31.23%.
Who are Jeena Sikho Lifecare's competitors?
The listed Pharma & Healthcare companies closest to Jeena Sikho Lifecare by market cap are Novartis India, Zota Health Care, RPG Life Sciences, Orchid Pharma, Gufic Biosciences and SMS Pharmaceuticals.
Is Jeena Sikho Lifecare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Jeena Sikho Lifecare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JSLL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with J · all NSE stocks · this page as text